Niraparib

A phase II trial evaluating niraparib and dostarlimab combination therapy in recurrent/metastatic head and neck squamous cell carcinoma was terminated early for futility after achieving only 20% clinical benefit versus the target of 50%.

The phase III AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improved radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer harboring HRR gene alterations.

UC Davis researchers conducted a Phase 2 trial testing niraparib as neoadjuvant therapy in 11 men with high-risk prostate cancer carrying specific DNA repair gene mutations.

• Taiwan's National Health Insurance Administration will expand coverage to include three types of cancer immunotherapies for lung, colorectal, and breast cancers, benefiting up to 3,400 patients starting June 2025. • The expansion will also cover two PARP inhibitors (olaparib and niraparib) for treating five cancer types, including ovarian, fallopian tube, peritoneal, breast, and prostate cancers, helping approximately 775 additional patients. • Patients could save between NT$1.71 million to NT$2.47 million annually in medical expenses, with the government allocating NT$3.295 billion from a dedicated cancer fund for immunotherapies.

• Phase II NERO study demonstrates GSK's Zejula (niraparib) reduced risk of disease progression or death by 27% in relapsed mesothelioma patients compared to standard care. • Patients treated with the PARP inhibitor gained an average of 1.5 months of progression-free survival, representing a significant advancement for a patient population with limited treatment options and poor prognosis. • University Hospital Southampton NHS Foundation Trust plans to launch SELECTmeso, a biomarker-driven Phase II platform trial to further personalize treatment approaches for mesothelioma patients.